Merial has announce the launch of Merilym 3, the first Lyme disease vaccine available in the UK. For use in dogs, the vaccine can be administered to puppies from 12 weeks old.
Merial has announce the launch of Merilym 3, the first Lyme disease vaccine available in the UK.
Lyme disease is the most common vector-borne disease in Europe, with an increase of more than 300% in the number of reported human cases in the UK since 20011. It is also common in dogs, particularly those that live near, or often visit tick-infested areas.
Caused by infection with bacteria from the Borrelia burgdorferi group, the disease is transmitted by Ixodes spp. ticks.
Many dogs infected with Lyme disease show no symptoms at all, but clinical signs can include recurrent lameness due to inflammation of the joints, a lack of appetite and depression. A small number of infected dogs may also develop kidney problems and, in rare cases, heart or nervous system disease.
The vaccine contains inactivated antigens from Borrelia burgdorferi sensu stricto, Borrelia afzelli and Borrelia garinii, so provides broad spectrum immunity against infection.
Vaccination with Merilym 3 induces high levels of antibodies against a key bacterial antigen, which are ingested by the tick during blood feeding and subsequently bind to the bacteria in the tick gut, reducing the risk of transmission from the tick to the host.
For use in dogs, the vaccine can be administered to puppies from 12 weeks old, with a primary vaccination course of two injections, three weeks apart, followed by annual boosters.
Merilym 3 is available in packs of 10 doses.
- Merial recommends that vets speak to their local territory manager about the vaccine and the range of pet owner communication materials.